Suppr超能文献

相似文献

1
Expanding Roles of the E2F-RB-p53 Pathway in Tumor Suppression.
Biology (Basel). 2023 Dec 11;12(12):1511. doi: 10.3390/biology12121511.
2
Deregulated E2F Activity as a Cancer-Cell Specific Therapeutic Tool.
Genes (Basel). 2023 Feb 2;14(2):393. doi: 10.3390/genes14020393.
4
E2F-1 transcriptional activity is a critical determinant of Mdm2 antagonist-induced apoptosis in human tumor cell lines.
Oncogene. 2008 Sep 11;27(40):5303-14. doi: 10.1038/onc.2008.164. Epub 2008 Jun 2.
6
Repression of the Arf tumor suppressor by E2F3 is required for normal cell cycle kinetics.
Genes Dev. 2004 Jun 15;18(12):1413-22. doi: 10.1101/gad.1196704. Epub 2004 Jun 2.
7
ARF promotes accumulation of retinoblastoma protein through inhibition of MDM2.
Oncogene. 2007 Jul 12;26(32):4627-34. doi: 10.1038/sj.onc.1210254. Epub 2007 Feb 5.
8
Cancer cell specific cytotoxic gene expression mediated by ARF tumor suppressor promoter constructs.
Biochem Biophys Res Commun. 2014 Jul 18;450(1):240-6. doi: 10.1016/j.bbrc.2014.05.102. Epub 2014 Jun 2.

引用本文的文献

1
CCDC138 overexpression predicts poor prognosis and highlights ciliopathy-linked mechanisms in uterine corpus endometrial carcinoma.
Front Mol Biosci. 2025 Aug 8;12:1622496. doi: 10.3389/fmolb.2025.1622496. eCollection 2025.
2
Functional Changes Associated With the Subcellular Localization of the Nuclear Receptor NR4A1.
Biochem Res Int. 2025 Jul 24;2025:4849733. doi: 10.1155/bri/4849733. eCollection 2025.
3
Molecular and Genetic Pathogenesis of Oral Cancer: A Basis for Customized Diagnosis and Treatment.
Biology (Basel). 2025 Jul 10;14(7):842. doi: 10.3390/biology14070842.
4
Advancements in Dalpiciclib for the Treatment of Breast Cancer Patients: A Review.
Breast Cancer (Dove Med Press). 2025 Jun 30;17:557-565. doi: 10.2147/BCTT.S529794. eCollection 2025.
7
Neurotropic Viruses as Acute and Insidious Drivers of Aging.
Biomolecules. 2025 Apr 1;15(4):514. doi: 10.3390/biom15040514.
9
Rhythms in Remodeling: Posttranslational Regulation of Bone by the Circadian Clock.
Biomedicines. 2025 Mar 13;13(3):705. doi: 10.3390/biomedicines13030705.
10
MEOX2 mediates cisplatin resistance in ovarian cancer via E2F target and DNA repair pathways.
J Ovarian Res. 2025 Mar 21;18(1):58. doi: 10.1186/s13048-025-01641-2.

本文引用的文献

1
Ferroptosis and the bidirectional regulatory factor p53.
Cell Death Discov. 2023 Jun 29;9(1):197. doi: 10.1038/s41420-023-01517-8.
2
An African-Specific Variant of TP53 Reveals PADI4 as a Regulator of p53-Mediated Tumor Suppression.
Cancer Discov. 2023 Jul 7;13(7):1696-1719. doi: 10.1158/2159-8290.CD-22-1315.
3
Crosstalk between Metabolite Production and Signaling Activity in Breast Cancer.
Int J Mol Sci. 2023 Apr 18;24(8):7450. doi: 10.3390/ijms24087450.
4
FAM193A is a positive regulator of p53 activity.
Cell Rep. 2023 Mar 28;42(3):112230. doi: 10.1016/j.celrep.2023.112230. Epub 2023 Mar 9.
5
Deregulated E2F Activity as a Cancer-Cell Specific Therapeutic Tool.
Genes (Basel). 2023 Feb 2;14(2):393. doi: 10.3390/genes14020393.
6
Targeted MDM2 Degradation Reveals a New Vulnerability for p53-Inactivated Triple-Negative Breast Cancer.
Cancer Discov. 2023 May 4;13(5):1210-1229. doi: 10.1158/2159-8290.CD-22-1131.
7
BCL-2 protein family: attractive targets for cancer therapy.
Apoptosis. 2023 Feb;28(1-2):20-38. doi: 10.1007/s10495-022-01780-7. Epub 2022 Nov 7.
8
PLTP is a p53 target gene with roles in cancer growth suppression and ferroptosis.
J Biol Chem. 2022 Dec;298(12):102637. doi: 10.1016/j.jbc.2022.102637. Epub 2022 Oct 26.
9
The current state of the art and future trends in RAS-targeted cancer therapies.
Nat Rev Clin Oncol. 2022 Oct;19(10):637-655. doi: 10.1038/s41571-022-00671-9. Epub 2022 Aug 26.
10
Coordinating gene expression during the cell cycle.
Trends Biochem Sci. 2022 Dec;47(12):1009-1022. doi: 10.1016/j.tibs.2022.06.007. Epub 2022 Jul 11.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验